Physician profile
Randolph Alan Chen
NPI 1962502872
$12,091.32
in general payments reported to CMS, 2019-2025
17 companies · $1,135 in 2025
The $1,135 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $728 · 2020: $107 · 2021: $318 · 2022: $1,208 · 2023: $3,003 · 2024: $5,593 · 2025: $1,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,638 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,400 · Consulting Fee: $2,100 · Travel and Lodging: $1,584 · Education: $9.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,637.76 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,400.00 |
| Consulting Fee | $2,100.00 |
| Travel and Lodging | $1,583.52 |
| Education | $9.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $5,187.44 | 2021-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $2,827.42 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,487.25 | 2021-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $924.19 | 2019-2024 | Veltassa |
| Amgen INC. | $342.19 | 2023-2025 | Tavneos, Parsabiv, Aranesp |
| Otsuka America Pharmaceutical, INC. | $215.83 | 2019 | |
| Travere Therapeutics, INC. | $189.89 | 2023-2025 | |
| Novo Nordisk INC | $154.84 | 2024-2025 | Ozempic |
| Calliditas Therapeutics US INC. | $153.92 | 2023-2025 | Tarpeyo |
| Nxstage Medical, INC. | $130.77 | 2025 | Nxstage System One, Liberty Select Cycler |
| Akebia Therapeutics INC | $129.58 | 2019 | |
| Bard Peripheral Vascular, INC. | $107.04 | 2020 | |
| Lilly USA, LLC | $74.74 | 2023-2025 | Jardiance, Mounjaro |
| Horizon Therapeutics Plc | $69.65 | 2022-2023 | Krystexxa |
| Ardelyx, INC. | $51.29 | 2024 | Ibsrela |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $23.41 | 2019 | |
| Aurinia Pharma U.S., INC. | $21.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randolph Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.